JP2024527293A5 - - Google Patents

Info

Publication number
JP2024527293A5
JP2024527293A5 JP2023579437A JP2023579437A JP2024527293A5 JP 2024527293 A5 JP2024527293 A5 JP 2024527293A5 JP 2023579437 A JP2023579437 A JP 2023579437A JP 2023579437 A JP2023579437 A JP 2023579437A JP 2024527293 A5 JP2024527293 A5 JP 2024527293A5
Authority
JP
Japan
Prior art keywords
binding protein
terminus
pharmaceutical composition
life
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023579437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034856 external-priority patent/WO2022272033A2/en
Publication of JP2024527293A publication Critical patent/JP2024527293A/ja
Publication of JP2024527293A5 publication Critical patent/JP2024527293A5/ja
Withdrawn legal-status Critical Current

Links

JP2023579437A 2021-06-25 2022-06-24 持続放出免疫細胞結合型タンパク質および処置方法 Withdrawn JP2024527293A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163214963P 2021-06-25 2021-06-25
US63/214,963 2021-06-25
US202163276804P 2021-11-08 2021-11-08
US63/276,804 2021-11-08
US202263328603P 2022-04-07 2022-04-07
US63/328,603 2022-04-07
PCT/US2022/034856 WO2022272033A2 (en) 2021-06-25 2022-06-24 Extended-release immune cell engaging proteins and methods of treatment

Publications (2)

Publication Number Publication Date
JP2024527293A JP2024527293A (ja) 2024-07-24
JP2024527293A5 true JP2024527293A5 (https=) 2025-06-30

Family

ID=84544696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579437A Withdrawn JP2024527293A (ja) 2021-06-25 2022-06-24 持続放出免疫細胞結合型タンパク質および処置方法

Country Status (7)

Country Link
US (1) US20240216518A1 (https=)
EP (1) EP4359443A4 (https=)
JP (1) JP2024527293A (https=)
CN (1) CN118251414A (https=)
AU (1) AU2022297538A1 (https=)
CA (1) CA3224137A1 (https=)
WO (1) WO2022272033A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3850013A4 (en) * 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
UY40797A (es) * 2023-06-14 2024-12-31 Amgen Inc Moléculas captadoras de enmascaramiento de células t
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025085761A1 (en) * 2023-10-19 2025-04-24 Harpoon Therapeutics, Inc. Dll3 targeting trispecific proteins and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2018204717A1 (en) * 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
BR112020023330A2 (pt) * 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
AU2020275002A1 (en) * 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use

Similar Documents

Publication Publication Date Title
JP2024527293A5 (https=)
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
ES2548767T3 (es) Nuevos péptidos antimicrobianos
AU2016204543B2 (en) Targeted antimicrobial moieties
JP2019112445A5 (https=)
JP2025137626A5 (https=)
JP2021521822A5 (https=)
JP2024102211A5 (https=)
WO2008073162A3 (en) Lysine acetylation sites
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
EP2400013A3 (de) Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2021073174A5 (https=)
JP2014193892A5 (https=)
WO2022272033A3 (en) Extended-release immune cell engaging proteins and methods of treatment
MX9706049A (es) Adresinas vasculares mucosas y sus usos.
WO2004019872A3 (en) Oral delivery of modified transferrin fusion proteins
JP2022512714A5 (https=)
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae
JP2006523185A5 (https=)
JP2009521512A5 (https=)
TW200505943A (en) Polypeptide
SI2952521T1 (en) Peptides derived from human BPLP protein, polynucleotides encoding these peptides, and antibodies directed against these peptides
JPH02276590A (ja) タンパク質抗ガン剤
GB1309150A (en) Acthactive peptides and process for their manufacture